portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 China Grand Pharm (HKG:0512) to boost stocks in GPCCL to 91.1%
 
CreateTime:2012-07-04     Source:chinesestock.org Editor:qulina
Text Size:       
 

Written resolutions have been passed by all the shareholders of Grand Pharmaceutical (China) Co., Limited (GPCCL), a 75.95%-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings (HKG:0512), to increase GPCCL's registered capital from RMB185 million to RMB498 million by injecting additional capital of RMB313 million, China Grand Pharmaceutical and Healthcare said.

China Grand Pharmaceutical and Healthcare has agreed to contribute the entire additional registered capital of GPCCL at a total consideration of RMB359.95 million, while the minority shareholders indicated that they will not contribute to the increase in registered capital of GPCCL in proportion fo their respective existing shareholding in GPCCL.

The injection will increase China Grand Pharmaceutical and Healthcare's equity interest in GPCCL to 91.07%.

 


Related Reports
China Animal Vaccine Industry Report, 2019-2025
China Blood Product Industry Report, 2020-2026
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1